TransMedics Group Inc
For the period ended Sep 30, 2024. Filed Oct 29, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 29, 2024
TMDX$90.95-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $28,607 | $(29,059) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||
| Depreciation and amortization expense | 14,078 | 4,572 |
| Stock-based compensation expense | 22,457 | 14,067 |
| Acquired in-process research and development expenses | — | 27,212 |
| Deferred taxes | — | (1,540) |
| Non-cash interest expense and end of term accretion expense | 2,327 | 1,358 |
| Non-cash lease expense | 1,102 | 728 |
| Unrealized foreign currency transaction (gains) losses | (280) | 118 |
| Loss on disposal of fixed assets | 17 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (26,469) | (30,997) |
| Inventory | (12,490) | (21,029) |
| Prepaid expenses and other current assets | (6,066) | (2,170) |
| Other non-current assets | (100) | (54) |
| Accounts payable | 1,742 | 6,541 |
| Accrued expenses and other current liabilities | 5,614 | 9,257 |
| Deferred revenue | 227 | 765 |
| Operating lease liabilities | (1,626) | (1,101) |
| Net cash provided by (used in) operating activities | 29,140 | (21,332) |
| Cash flows from investing activities: | ||
| Purchases of property, plant and equipment | (116,138) | (110,029) |
| Purchase of business, net of cash acquired | 441 | (14,894) |
| Purchase of in-process research and development assets | — | (27,212) |
| Net cash used in investing activities | (115,697) | (152,135) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of convertible senior notes, net of issuance costs paid of $14,620 | — | 445,380 |
| Purchases of capped calls related to convertible senior notes | — | (52,072) |
| Proceeds from issuance of common stock upon exercise of stock options | 19,627 | 5,231 |
| Proceeds from issuance of common stock in connection with employee stock purchase plan | 2,061 | 955 |
| Net cash provided by financing activities | 21,688 | 399,494 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 151 | (99) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (64,718) | 225,928 |
| Cash, cash equivalents and restricted cash, beginning of period | 395,312 | 201,682 |
| Cash, cash equivalents and restricted cash, end of period | $330,594 | $427,610 |
| Supplemental disclosure of non-cash activities: | ||
| Transfers of inventory to property, plant and equipment | $4,588 | $2,224 |
| Purchases of property, plant and equipment included in accounts payable and accrued expenses | $930 | $1,724 |
| Operating lease liabilities arising from obtaining right-of-use assets | $1,499 | $2,171 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $330,094 | $427,110 |
| Restricted cash | 500 | 500 |
| Total cash, cash equivalents and restricted cash shown in the statement of cash flows | $330,594 | $427,610 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.